⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XRTX News
XORTX Therapeutics Inc. Common Stock
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
globenewswire.com
XRTX
Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026
globenewswire.com
AZN
LLY
REGN
IONS
MRK
XRTX
DMAC
LSTA
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
globenewswire.com
XRTX
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
globenewswire.com
XRTX
XORTX Re-Engages Investor Relations Program
globenewswire.com
XRTX
XORTX Announces Termination and Postponement of Investor Relations Program
globenewswire.com
XRTX
XORTX Announces Director Resignation
globenewswire.com
XRTX
XORTX Appoints New Director
globenewswire.com
XRTX
Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsight
globenewswire.com
FMS
BIIB
MDT
NVO
LLY
AZN
RDNT
LXRX
SNY
XRTX
RGEN
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE